Restricted accessResearch articleFirst published online 2008-9
Remission of Chronic Severe Selective Serotonin-Reuptake Inhibitor/Selective Norepinephrine-Reuptake Inhibitor Refractory Depression Following Adjunctive Aripiprazole
BermanRM, MarcusRN, SwaninkR. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo controlled study. J Clin Psychiatry2007;68:843–53.
2.
MarcusRN, McQuadeRD, CarsonWH. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol2008;28:156–65.
3.
PapakostasGI, PetersenTJ, KinrysG. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry2005;66:1326–30.
4.
SimonJS, NemeroffCB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J Clin Psychiatry2005;66:1216–20.
5.
HellersteinDJ, BatcheldarS, HylerS. Aripiprazole as an adjunctive treatment for refractory unipolar depression. Prog Neuropsychopharmacol Biol Psychiatry2008;32:744–50.
